Treatment Options for Juvenile Pityriasis Rubra Pilaris

Pityriasis rubra pilaris represents a group of familial and acquired disorders of cornification that affect both adult and pediatric patients. Treatment options are difficult to assess through clinical trials, given the rarity of the disorder and its tendency for spontaneous remission. Case reports and case series are therefore the primary means of assessment. Because of the heterogeneity of the disease, there is no universal approach to treatment, and multiple agents may need to be trialed to achieve disease control. At present, topicals are used for most pediatric patients, though monotherapy with topicals is only effective for less severe disease. Despite concerns over their side-effect profiles, oral retinoids are generally accepted as a first-line systemic therapy. However, interleukin-17 inhibitors and ustekinumab, an interleukin-12 and interleukin-23 inhibitor, may soon become first-line systemic treatment as well, given their efficacy and relative safety in trials thus far. Ustekinumab, in particular, is emerging as a first-line agent for patients with pityriasis rubra pilaris with CARD14 gene variations. When these therapies fail, second-line and adjunctive therapies to consider include tumor necrosis factor-alpha inhibitors, methotrexate, and phototherapy. However, further investigation is necessary to assess the safety and efficacy of many of these agents in juvenile pityriasis rubra pilaris.

Automated summary

Pityriasis rubra pilaris is a rare disorder of cornification that affects both adult and pediatric patients, making clinical trials and universal treatment approaches challenging. Case reports and case series are the primary means of assessment for treatment options. Topicals are commonly used for pediatric patients, while oral retinoids are generally accepted as a first-line therapy. Interleukin-17 inhibitors and ustekinumab may also become first-line treatments due to their efficacy and relative safety. Second-line and adjunctive therapies such as tumor necrosis factor-alpha inhibitors, methotrexate, and phototherapy can be considered if initial treatments fail.